Hayek Kallen Investment Management lessened its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,742 shares of the company’s stock after selling 715 shares during the quarter. Johnson & Johnson makes up about 2.4% of Hayek Kallen Investment Management’s holdings, making the stock its 10th largest position. Hayek Kallen Investment Management’s holdings in Johnson & Johnson were worth $5,385,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the business. Reston Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 4.4% during the first quarter. Reston Wealth Management LLC now owns 1,652 shares of the company’s stock worth $256,000 after purchasing an additional 70 shares during the last quarter. HC Advisors LLC grew its holdings in shares of Johnson & Johnson by 15.9% during the first quarter. HC Advisors LLC now owns 2,104 shares of the company’s stock worth $326,000 after purchasing an additional 288 shares during the last quarter. Cambiar Investors LLC purchased a new position in shares of Johnson & Johnson during the first quarter worth about $39,023,000. Laurel Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson by 5.5% during the first quarter. Laurel Wealth Advisors LLC now owns 60,907 shares of the company’s stock worth $9,440,000 after purchasing an additional 3,163 shares during the last quarter. Finally, Live Oak Private Wealth LLC grew its holdings in shares of Johnson & Johnson by 3.9% during the first quarter. Live Oak Private Wealth LLC now owns 8,071 shares of the company’s stock worth $1,251,000 after purchasing an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 67.57% of the company’s stock.
Johnson & Johnson Trading Down 0.3 %
Shares of JNJ opened at $172.92 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The firm has a 50 day simple moving average of $165.50 and a 200-day simple moving average of $161.20. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The stock has a market cap of $449.41 billion, a price-to-earnings ratio of 35.00, a price-to-earnings-growth ratio of 2.92 and a beta of 0.54.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.75%. Johnson & Johnson’s payout ratio is currently 96.36%.
Wall Street Analyst Weigh In
JNJ has been the topic of several research reports. Atlantic Securities raised their price objective on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Citigroup started coverage on shares of Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 target price for the company. JPMorgan Chase & Co. increased their target price on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Barclays increased their target price on shares of Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Monday, July 24th. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They set a “strong-buy” rating for the company. Eight equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $171.80.
Get Our Latest Stock Analysis on JNJ
Insiders Place Their Bets
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. In the last three months, insiders sold 47,163 shares of company stock valued at $7,928,856. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Investing in Construction Stocks
- On Holding Slips Into A More Comfortable Price PointÂ
- What Makes a Stock a Good Dividend Stock?
- 3 Growing Cannabis Stocks Ready To Bloom
- What is a Special Dividend?
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
